Reference number : 276-2014-2015-Q4-00183, amendment number : , agreement type : C, recipient legal name : ImmunoVaccine Technologies Inc.|ImmunoVaccine Technologies Inc., recipient country : CA, recipient province : NS, recipient city : Halifax|Halifax, recipient postal code : B3H 0A8, program name english : Business Development Program, program name french : Programme de développement des entreprises, program purpose english : nan, program purpose french : nan, agreement title english : 204891, agreement title french : 204891, agreement number : 204891, agreement value : 394826.0, agreement start date : 2015-02-04, agreement end date : 2015-04-30, description english : Facilitate a GMP clinical vaccine manufacture, description french : Faciliter une usine clinique de fabrication de vaccins BPF, expected results english : nan, expected results french : nan, additional information english : The assistance type is Unconditionally Repayable Contribution., additional information french : Le type d'aide est Contribution à remboursement inconditionnel., owner organization : acoa-apeca, owner organization title : Atlantic Canada Opportunities Agency | Agence de promotion économique du Canada atlantique